<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001943'>Hypoglycemia</z:hpo> is well-recognized to limit the degree of glycemic control possible for many individuals for <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Although the likelihood of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> increases as A1c levels decrease in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, insulin-treated type 2 diabetic persons with higher A1c appear paradoxically to have more <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> which may explain, in part, the adverse outcome reported in the ACCORD study </plain></SENT>
<SENT sid="2" pm="."><plain>Approaches to <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering that cause lesser degrees of risk for <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, technologies to better ascertain hypoglycemic events, and better understanding of patient characteristics associated with greater likelihood of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> will <z:hpo ids='HP_0000001'>all</z:hpo> be required to reduce this limiting factor in optimizing glycemic treatment </plain></SENT>
</text></document>